182 related articles for article (PubMed ID: 12731328)
1. [Multivariate analysis of recurrence and progression in stage T1 transitional-cell carcinoma of the bladder. Prognostic value of p53 and Ki67].
Rodríguez Alonso A; Pita Fernández S; González-Carreró J; Nogueira March JL
Actas Urol Esp; 2003 Feb; 27(2):132-41. PubMed ID: 12731328
[TBL] [Abstract][Full Text] [Related]
2. p53 and ki67 expression as prognostic factors for cancer-related survival in stage T1 transitional cell bladder carcinoma.
Rodríguez-Alonso A; Pita-Fernández S; González-Carreró J; Nogueira-March JL
Eur Urol; 2002 Feb; 41(2):182-8; discussion 188-9. PubMed ID: 12074407
[TBL] [Abstract][Full Text] [Related]
3. Multivariate analysis of survival, recurrence, progression and development of mestastasis in T1 and T2a transitional cell bladder carcinoma.
Rodríguez-Alonso A; Pita-Fernández S; González-Carreró J; Nogueira-March JL
Cancer; 2002 Mar; 94(6):1677-84. PubMed ID: 11920528
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of P53 protein overexpression, Ki67 proliferative activity and mitotic index as markers of tumour recurrence in superficial transitional cell carcinoma of the bladder.
Gontero P; Casetta G; Zitella A; Ballario R; Pacchioni D; Magnani C; Muir GH; Tizzani A
Eur Urol; 2000 Sep; 38(3):287-96. PubMed ID: 10940702
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of MCM2 immunoreactivity in stage T1 transitional cell carcinoma of the bladder.
Krüger S; Thorns C; Stöcker W; Müller-Kunert E; Böhle A; Feller AC
Eur Urol; 2003 Feb; 43(2):138-45. PubMed ID: 12565771
[TBL] [Abstract][Full Text] [Related]
6. Cyclin D1 expression in transitional cell carcinoma of the bladder: correlation with p53, waf1, pRb and Ki67.
Tut VM; Braithwaite KL; Angus B; Neal DE; Lunec J; Mellon JK
Br J Cancer; 2001 Jan; 84(2):270-5. PubMed ID: 11161387
[TBL] [Abstract][Full Text] [Related]
7. Prospective evaluation of Ki-67 labeling in predicting the recurrence and progression of superficial bladder transitional cell carcinoma.
Blanchet P; Droupy S; Eschwege P; Viellefond A; Paradis V; Pichon MF; Jardin A; Benoit G
Eur Urol; 2001 Aug; 40(2):169-75. PubMed ID: 11528194
[TBL] [Abstract][Full Text] [Related]
8. Clinical significance of mdm2 and p53 expression in bladder cancer. A comparison with cell proliferation and apoptosis.
Shiina H; Igawa M; Shigeno K; Yamasaki Y; Urakami S; Yoneda T; Wada Y; Honda S; Nagasaki M
Oncology; 1999 Apr; 56(3):239-47. PubMed ID: 10202280
[TBL] [Abstract][Full Text] [Related]
9. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression.
Sarkis AS; Dalbagni G; Cordon-Cardo C; Zhang ZF; Sheinfeld J; Fair WR; Herr HW; Reuter VE
J Natl Cancer Inst; 1993 Jan; 85(1):53-9. PubMed ID: 7677935
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of Ki-67 for recurrence and progression of superficial bladder cancer.
Asakura T; Takano Y; Iki M; Suwa Y; Noguchi S; Kubota Y; Masuda M
J Urol; 1997 Aug; 158(2):385-8. PubMed ID: 9224308
[TBL] [Abstract][Full Text] [Related]
11. [Comparative study of the expression of p53, Ki-67, bcl-2 and CK20 in superficial transitional carcinoma of the bladder: correlation with recurrence, histological grade, and clinical stage].
San Miguel Fraile P; Antón Badiola I; Ortiz Rey JA; Alvarez Alvarez C; Fernández Costas A; Lago Fernández M; Pelaez Boismorand E; Zungri Telo E; De La Fuente Buceta A
Actas Urol Esp; 2003 Sep; 27(8):587-93. PubMed ID: 14587233
[TBL] [Abstract][Full Text] [Related]
12. Cell-cycle markers do not improve discrimination of EORTC and CUETO risk models in predicting recurrence and progression of non-muscle-invasive high-grade bladder cancer.
Passoni N; Gayed B; Kapur P; Sagalowsky AI; Shariat SF; Lotan Y
Urol Oncol; 2016 Nov; 34(11):485.e7-485.e14. PubMed ID: 27637323
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of proliferative activity and nuclear morphometry for progression in TaT1 urothelial cell carcinomas of the urinary bladder.
Bol MG; Baak JP; Rep S; Marx WL; Kruse AJ; Bos SD; Kisman O; Voorhorst FJ
Urology; 2002 Dec; 60(6):1124-30. PubMed ID: 12475695
[TBL] [Abstract][Full Text] [Related]
14. [Reply to the letter: "In reference to the article: Multivariate analysis of recurrence and progression of stage T1 transitional cell carcinoma of the bladder. Prognostic value of p53 and kI67].
Rodríguez Alonso A; Pita Fernández S
Actas Urol Esp; 2003 Oct; 27(9):746-7. PubMed ID: 14626689
[No Abstract] [Full Text] [Related]
15. Proliferation markers and DNA content analysis in urinary bladder TaT1 urothelial cell carcinomas: identification of subgroups with low and high stage progression risks.
Bol MG; Baak JP; van Diermen B; Buhr-Wildhagen S; Janssen EA; Kjellevold KH; Kruse AJ; Mestad O; Øgreid P
J Clin Pathol; 2003 Jun; 56(6):447-52. PubMed ID: 12783972
[TBL] [Abstract][Full Text] [Related]
16. Primary superficial bladder cancer risk groups according to progression, mortality and recurrence.
Millán-Rodríguez F; Chéchile-Toniolo G; Salvador-Bayarri J; Palou J; Algaba F; Vicente-Rodríguez J
J Urol; 2000 Sep; 164(3 Pt 1):680-4. PubMed ID: 10954628
[TBL] [Abstract][Full Text] [Related]
17. Prognostic significance of p53, bcl-2 and Ki-67 in high risk superficial bladder cancer.
Stavropoulos NE; Filiadis I; Ioachim E; Hastazeris K; Tsimaris I; Kalogeras D; Stefanaki S; Agnantis NJ
Anticancer Res; 2002; 22(6B):3759-64. PubMed ID: 12552989
[TBL] [Abstract][Full Text] [Related]
18. Prognostic value of the combined expression of tumor-associated trypsin inhibitor (TATI) and p53 in patients with bladder cancer undergoing radical cystectomy.
Liu A; Xue Y; Liu F; Tan H; Xiong Q; Zeng S; Zhang Z; Gao X; Sun Y; Xu C
Cancer Biomark; 2019; 26(3):281-289. PubMed ID: 31594208
[TBL] [Abstract][Full Text] [Related]
19. p53 expression compared with other prognostic factors in OMS grade-I stage-Ta transitional cell carcinoma of the bladder.
Casetta G; Gontero P; Russo R; Pacchioni D; Tizzani A
Eur Urol; 1997; 32(2):229-36. PubMed ID: 9286659
[TBL] [Abstract][Full Text] [Related]
20. MIB-1 as a proliferative marker in transitional cell carcinoma of the bladder: clinical significance and comparison with other prognostic factors.
Oosterhuis JW; Schapers RF; Janssen-Heijnen ML; Smeets AW; Pauwels RP
Cancer; 2000 Jun; 88(11):2598-605. PubMed ID: 10861439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
